CD14-negative isolation enhances chondrogenesis in synovial fibroblasts.
Synovial membrane has been shown to contain mesenchymal stem cells. We hypothesized that an enriched population of synovial fibroblasts would undergo chondrogenic differentiation and secrete cartilage extracellular matrix to a greater extent than would a mixed synovial cell population (MSCP). The optimum doses of transforming growth factor beta 1 (TGF-beta1) and insulin-like growth factor 1 (IGF-1) for chondrogenesis were investigated. CD14-negative isolation was used to obtain a porcine cell population enriched in type-B synovial fibroblasts (SFB) from an MSCP. The positive cell surface markers in SFB were CD90, CD44, and cadherin-11. SFB and MSCP were cultured in the presence of 20 ng/mL TGF-beta1 for 7 days, and SFB were demonstrated to have higher chondrogenic potential. Further dose-response studies were carried out using the SFB cells and several doses of TGF-beta1 (2, 10, 20, and 40 ng/mL) and/or IGF-1 (1, 10, 100, and 500 ng/mL) for 14 days. TGF-beta1 supplementation was essential for chondrogenesis and prevention of cell death, whereas IGF-1 did not have a significant effect on the SFB cell number or glycosaminoglycan production. This study demonstrates that the CD14-negative isolation yields an enhanced cell population SFB that is more potent than MSCP as a cell source for cartilage tissue engineering.
Bilgen
Bahar
B
Department of Orthopaedics, Alpert Medical School of Brown University and Center for Restorative and Regenerative Medicine, Providence VA Medical Center and Brown University, Providence, Rhode Island 02903, USA.
Ren
Yuexin
Y
Pei
Ming
M
Aaron
Roy K
RK
Ciombor
Deborah McK
DM
D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods; D002478:Cells, Cultured; D020219:Chondrogenesis / Q000187:drug effects / Q000502:physiology*; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D018960:Hyaluronan Receptors / Q000378:metabolism*; D013552:Swine; D013583:Synovial Membrane / Q000166:cytology* / Q000187:drug effects / Q000503:physiopathology*; D023822:Tissue Engineering / Q000379:methods; D053773:Transforming Growth Factor beta1 / Q000378:metabolism / Q000494:pharmacology*
D018960:Hyaluronan Receptors; D053773:Transforming Growth Factor beta1